Search

Displaying results 3221 - 3230 of 3600 in total
  1. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

    Categories: P-glycoprotein inhibitors
  3. Drug

    Rufinamide

    go.drugbank.com/drugs/DB06201
    Approved

    Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures.

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  4. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  6. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...

    Categories: Endothelin Receptor Antagonists, Cytochrome P-450 Substrates
  7. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the E...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    Simeprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated in patient's with HCV genotype 1 for the treatment of chronic hepatitis C virus (HCV) infection. HCV is a single-stranded RNA virus that is categorized into nine...

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    AVE9633

    go.drugbank.com/drugs/DB06318
    Investigational

    AVE9633 is an anti-CD33 monoclonal antibody-DM4 conjugate.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  10. Drug

    Saxagliptin

    go.drugbank.com/drugs/DB06335
    ApprovedInvestigational

    Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates